Actively Recruiting
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Led by University of Illinois at Chicago · Updated on 2026-01-29
24
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
N
National Eye Institute (NEI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
CONDITIONS
Official Title
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Chronic corneal epithelial disease with fluorescein staining score 6 by NEI grading scale or persistent corneal epithelial defect present for longer than 14 days despite standard treatment
- No significant improvement or worsening of the epithelial disease in the last 14 days
- Epithelial disease refractory to conventional non-surgical treatments such as preservative-free artificial tears, gels, ointments, discontinuation of preserved topical drops, or anti-inflammatory therapy
- If both eyes meet inclusion criteria, only the eye with the higher staining score will be enrolled
- Ability and willingness to comply with study procedures
- Signed informed consent form approved by UIC IRB
You will not qualify if you...
- Any active or suspected ocular infection (bacterial, viral, fungal, or protozoal)
- History of any ocular surgery, including laser or refractive procedures, in the study eye within the past 3 months
- Treatment with Oxervate in the study eye within 12 months
- Known hypersensitivity to components of study or procedural medications (e.g., fluorescein)
- Use of any investigational agent within 4 weeks of screening
- Participation in another clinical study at the same time
- Pregnancy at the time of enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
A
Ali R Djalilian, MD
CONTACT
C
Charlotte E Joslin, OD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here